Analysts Lower Zimmer Biomet Price Target Amid Reiteration

Zimmer Biomet shares plunged approximately 10.5% to $82.84 on April 29 — a 13-year low — despite reporting Q1 2026 results that beat analyst estimates on both revenue and earnings. Adjusted EPS came in at $2.09 versus the $1.87 consensus, and revenue of $2.09 billion beat the $2.06 billion estimate with organic growth of 2.9%. The selloff was triggered by the sudden resignation of CFO Suketu Upadhyay, effective immediately, with Paul Stellato named interim CFO — a leadership change that rattled investor confidence in execution continuity.

The abrupt CFO departure prompted a wave of analyst target cuts. Stifel lowered its target to $105 from $110, Truist cut to $92 from $98 (maintaining Hold and citing execution risk), JPMorgan trimmed to $95 from $100, Citi reduced to $94 from $98, and Canaccord cut to $83. Despite the target reductions, most analysts maintained their ratings, suggesting the underlying business fundamentals remain intact but management stability is now a near-term overhang for ZBH.

Zimmer Biomet raised its full-year EPS guidance to $8.40–$8.55 from $8.30–$8.45, partly aided by a $0.20 per share tariff-related benefit realized in Q1 that may partly represent a pull-forward from H2 2026. Revenue growth guidance was held at 2.5%–4.5%. The orthopedic device market remains structurally attractive given aging demographics and rising total joint replacement volumes, but investors will demand clarity on CFO succession before the stock can sustainably recover from its multi-year low.

Related Stocks

• ZBH
• TFC